# A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension

Study · id `cardio:ct-nct05147805` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05147805](<https://clinicaltrials.gov/study/NCT05147805>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05147805

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 102 participants.

## Technical summary

Registry record NCT05147805. Randomized; double masking; primary purpose treatment. Start 2022-08-24 (actual); primary completion 2025-03-27 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 102 participants (enrolled count; ClinicalTrials.gov record NCT05147805, source copy `cardio:ctgov-nct05147805-2026-03-30`, retrieved 2026-10-31)
- Started: 2022-08-24 (actual) (ClinicalTrials.gov record NCT05147805, source copy `cardio:ctgov-nct05147805-2026-03-30`, retrieved 2026-10-31)
- Primary completion: 2025-03-27 (actual) (ClinicalTrials.gov record NCT05147805, source copy `cardio:ctgov-nct05147805-2026-03-30`, retrieved 2026-10-31)
- Completion: 2025-03-27 (actual) (ClinicalTrials.gov record NCT05147805, source copy `cardio:ctgov-nct05147805-2026-03-30`, retrieved 2026-10-31)
- Countries: United States; Argentina; Australia; Austria; Belgium; Brazil; Denmark; Germany; Italy; Japan; Malaysia; Mexico; Philippines; Serbia; Spain; Switzerland; United Kingdom (ClinicalTrials.gov record NCT05147805, source copy `cardio:ctgov-nct05147805-2026-03-30`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05147805-2026-03-30`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension
- Condition: Pulmonary Arterial Hypertension
- Intervention (Drug): Treprostinil Palmitil
- Intervention (Drug): Placebo
- Lead sponsor: Insmed Incorporated
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`)
- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Registry lists this organization as the lead sponsor: Insmed Incorporated (`cardio:org-insmed-incorporated`)

## Provenance

Content hash: 75c167fc82c7a73abc2cc496503dc054f43c871fcca9582d03177e9895554884
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
